MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma su...
MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
About this item
Full title
Author / Creator
Publisher
England
Journal title
Language
English
Formats
Publication information
Publisher
England
More information
Scope and Contents
Contents
Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each year in the UK. The introduction of biological therapies has improved outcomes for the majority of patients with MM, but in approximately 20% of patients the tumour is characterised by genetic changes which confer a significantly poorer prognosis, generally termed high-risk...
Alternative Titles
Full title
MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_33762245
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_33762245
Other Identifiers
ISSN
2044-6055
E-ISSN
2044-6055
DOI
10.1136/bmjopen-2020-046225
